Program
ARN-75039
A development code. Also written as “ARN-75039 high”, “ARN-75039 low” and “ARN-75039 oral capsules”.
Its studies are mostly in Neglected Diseases, led by Arisan Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arisan Therapeutics | 30 open or running | phase 2since Feb 2, 2026 | Jan 27, 2023 | none ahead |
Also a collaborator on its studies: federal-medical-centre-owo.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 27, 2023First study: phase 1 study in Healthy Adult ParticipantsFirst studyNCT05735249 · 94 enrolled · United States
- Mar 13, 2025Phase 1 study in Healthy VolunteerNCT06911242 · 16 enrolled · United States
- Feb 2, 2026Phase 2 study in Lassa FeverPhase 2 reachedNCT07419373 · 135 enrolled · United States, Nigeria
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07419373Lassa Fever · United States, Nigeria | 2 | Suspended | Jun 2027 | 135 |
| NCT06911242Healthy Volunteer · United States | 1 | Completed | Apr 21, 2025 | 16 |
| NCT05735249Healthy Adult Participants · United States | 1 | Completed | Mar 28, 2025 | 94 |
How it is read
Names in the registry
- “ARN-75039 high”, 1 entry
- “ARN-75039 low”, 1 entry
- “ARN-75039 oral capsules”, 1 entry
- “ARN-75039”, 1 entry
Codes read as this program: ARN75039.
Conditions, from the studies’ own filings
- Neglected Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.